Idecabtagene vicleucel

Generic Name: Idecabtagene vicleucel

Brand Names: Abecma

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: 8PX1X7UG4D

Background: Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide, a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal antibody like isatuximab.

Idecabtagene vicleucel, also known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like axicabtagene ciloleucel and brexucabtagene autoleucel. These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen. The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain. Idecabtagene vicleucel is indicated as a fifth line treatment of adult patients with relapsed or refractory multiple myeloma.

Idecabtagene vicleucel was granted FDA approval on 26 March 2021.

Indication: Idecabtagene vicleucel is indicated to treat adult patients with relapsed or refractory multiple myeloma who have tried at least 4 other lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 monoclonal antibody.

Associated Conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma

Associated Therapies: -

Clinical Trials

CAR T-Cell Therapy Gains Ground

CAR T-cell therapy patients at Duke nearly doubled last fiscal year, driven by FDA approvals for new treatments and reduced access barriers. Duke's unique approach includes financial and logistical support for patients, emphasizing patient and family care.

cancer.gov

2 years ago

Tecvayli Produces Promising Results in Multiple Myeloma

Teclistamab, an experimental immunotherapy, shows promise for advanced multiple myeloma, with nearly two-thirds of trial participants responding and almost 40% achieving complete remission. Approved in the EU and under FDA review in the US, it targets BCMA protein, offering a new option for patients with limited treatments. Despite strong responses, infection risks and high costs remain concerns.

cancer.gov

3 years ago

FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma

FDA approved ciltacabtagene autoleucel (Carvykti) for refractory or relapsed multiple myeloma, offering a new CAR T-cell therapy option. It targets BCMA on myeloma cells, showing high response rates and remission lasting ~22 months in trials. Despite its high cost and limited availability, it represents a significant advancement in treatment, with manageable side effects similar to other CAR T-cell therapies.

biopharmadive.com

4 years ago

J&J's new cancer drug leads a growing pipeline of dual-targeting treatments

The FDA approved Johnson & Johnson's Rybrevant, a bispecific antibody for treating a specific mutation in non-small cell lung cancer. Bispecific antibodies, targeting two proteins simultaneously, are emerging as a promising treatment for various cancers, including lymphoma, leukemia, and multiple myeloma, with several drugs in advanced clinical trials.

cancer.gov

4 years ago

CAR T-Cell Therapy Approved for Multiple Myeloma

CAR T-cell therapy, specifically idecabtagene vicleucel (Abecma), was FDA-approved for multiple myeloma patients unresponsive to prior treatments. In a study, 72% of participants saw tumor reduction, with remissions lasting a median of 11 months. Despite its effectiveness, the therapy can cause severe side effects and is costly, priced at $419,500 per infusion.

researchandmarkets.com

14 years ago

CAR-T Cell Therapy Market - Market Size, Forecasts, Trials

CAR-T cell therapy, a groundbreaking immunotherapy, modifies patient T-cells to target and destroy cancer cells, acting as 'living drugs.' With 11 products commercialized, including 7 FDA-approved, the therapy shows promise in treating blood cancers. Challenges include expanding to solid tumors, reducing 'vein-to-vein' time, and improving reimbursement. The industry is advancing through gene-transfer techniques, partnerships, and 'on-off' switches in CAR-T cells to enhance efficacy and safety.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy